Legal & General Group Plc Purchases Shares of 20,548 Castle Biosciences, Inc. $CSTL

Legal & General Group Plc purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,548 shares of the company’s stock, valued at approximately $490,000. Legal & General Group Plc owned 0.07% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of CSTL. The Manufacturers Life Insurance Company acquired a new position in shares of Castle Biosciences in the 2nd quarter valued at about $299,000. Algert Global LLC boosted its stake in shares of Castle Biosciences by 102.7% in the second quarter. Algert Global LLC now owns 70,478 shares of the company’s stock worth $1,681,000 after buying an additional 35,700 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Castle Biosciences during the second quarter worth about $7,912,000. Quantbot Technologies LP purchased a new position in Castle Biosciences during the second quarter valued at approximately $62,000. Finally, Green Alpha Advisors LLC purchased a new position in Castle Biosciences during the second quarter valued at approximately $237,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CSTL shares. Roth Capital assumed coverage on Castle Biosciences in a research report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price objective on the stock. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a report on Friday, May 29th. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Activity

In other news, insider Tobin Juvenal sold 9,050 shares of Castle Biosciences stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total value of $317,112.00. Following the sale, the insider owned 66,914 shares in the company, valued at $2,344,666.56. This trade represents a 11.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 12,428 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $33.20, for a total transaction of $412,609.60. Following the transaction, the insider owned 21,479 shares of the company’s stock, valued at approximately $713,102.80. This trade represents a 36.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,517 shares of company stock worth $5,612,900 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Castle Biosciences Stock Down 0.5%

Castle Biosciences stock opened at $32.76 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The stock has a market capitalization of $1.00 billion, a PE ratio of -49.64 and a beta of 0.99. The business has a 50 day simple moving average of $28.66 and a 200-day simple moving average of $25.43. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.